Next 10 |
home / stock / mor / mor articles
MorphoSys AG (NASDAQ:MOR) is reportedly facing a burgeoning safety concern surrounding pelabresib, an experimental myelofibrosis treatment. My...
Tuesday, Incyte Corporation (NASDAQ:INCY) agreed to acquire Escient Pharmaceuticals for $750 million. Escient’s pipe...
Monday, Novartis AG (NYSE:NVS) made a voluntary public takeover offer to acquire MorphoSys AG (NASDAQ:MOR) for ?...
MorphoSys AG (NASDAQ:MOR) shares are trading higher Monday following a report suggesting Novartis AG (NYSE:NVS) is in talks to acquire the company....
U.S. stocks traded lower, with the Dow Jones falling over 300 points on Monday. Shares of The Estée Lauder Companies Inc. (NYSE: EL) rose s...
U.S. stock futures were mixed this morning, with the Dow futures falling around 50 points on Monday. Shares of Koninklijke Philips N.V. (NYSE: PHG...
Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session. TransCode Therapeutics priced a 5,942,623 share c...
Shares of Super Micro Computer, Inc. (NASDAQ: SMCI) rose sharply in pre-market trading after the company announced updated financial guidance for ...
U.S. stock futures were higher this morning, with the Nasdaq futures gaining over 100 points on Friday. Shares of iRobot Corporation (NASDAQ: IRBT...
News, Short Squeeze, Breakout and More Instantly...
MorphoSys AG Company Name:
MOR Stock Symbol:
NASDAQ Market:
2024-04-30 06:15:05 ET Oddo BHF analyst issues NEUTRAL recommendation for MOR on April 30, 2024 04:35AM ET. MOR was trading at $17.36 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 3 - Buy, 1 - Hold, 1 -...
MorphoSys AG (NASDAQ:MOR) is reportedly facing a burgeoning safety concern surrounding pelabresib, an experimental myelofibrosis treatment. My...
– Entered into Business Combination Agreement to be acquired by Novartis for € 68.00 per share in cash, representing a total equity value of € 2.7 billion – Received all mandatory antitrust approvals for the proposed acquisition by Novartis – S...